ArticleRegulatory peptides2007
Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) receptor specific peptide analogues for PET imaging of breast cancer: In vitro/in vivo evaluation.
Article in Regulatory peptides, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 38 citations in OpenAlex.
- Targeting genomic receptors in voided urine for confirmation of benign prostatic hyperplasia.BJUI compass · 2024Article
- Targeting the Oxytocin Receptor for Breast Cancer Management: A Niche for Peptide Tracers.Journal of medicinal chemistry · 2024Review
- Activation of VIPR1 suppresses hepatocellular carcinoma progression by regulating arginine and pyrimidine metabolism.International journal of biological sciences · 2022Article
- Targeting VPAC1 Receptors for Imaging Glioblastoma.Molecular imaging and biology · 2020Article
- VPAC1-targeted PET/CT scan: improved molecular imaging for the diagnosis of prostate cancer using a novel cell surface antigen.World journal of urology · 2018Review
- VPAC1 TargetedNuclear medicine and biology · 2017Article
- Development of a voided urine assay for detecting prostate cancer non-invasively: a pilot study.BJU international · 2017Article
- Review: Receptor Targeted Nuclear Imaging of Breast Cancer.International journal of molecular sciences · 2017Review
- VPAC1 Targeted (64)Cu-TP3805 Positron Emission Tomography Imaging of Prostate Cancer: Preliminary Evaluation in Man.Urology · 2016Article
- Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer.Current opinion in endocrinology, diabetes, and obesity · 2016Review
- Evaluation of a PACAP Peptide Analogue Labeled with (68)Ga Using Two Different Chelating Agents.Cancer biotherapy & radiopharmaceuticals · 2016Article
- VPAC2 receptor expression in human normal and neoplastic tissues: evaluation of the novel MAB SP235.Endocrine connections · 2015Article
- Modulation, bioinformatic screening, and assessment of small molecular peptides targeting the vascular endothelial growth factor receptor.Cell biochemistry and biophysics · 2014Article
- A neuropeptide speeds circadian entrainment by reducing intercellular synchrony.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- VPAC1 receptors for imaging breast cancer: a feasibility study.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2013Article
- Development of copper based drugs, radiopharmaceuticals and medical materials.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2012Review
- Rationale for the use of radiolabelled peptides in diagnosis and therapy.European journal of nuclear medicine and molecular imaging · 2012Review
- Chemical modification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies.Pharmacology & therapeutics · 2010Review
- Genomic biomarkers for molecular imaging: predicting the future.Seminars in nuclear medicine · 2009Review
- PET imaging of VPAC1 expression in experimental and spontaneous prostate cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Vasoactive intestinal peptide and pituitary adenylate cyclase activating peptide have high affinity for VPAC1, VPAC2 and PAC1 receptors overexpressed on human cancer cells. Four potent analogues of these peptides, TP3939, TP3982, TP4200 and TP3805 were labeled with (64)Cu and evaluated ex vivo and in vivo to asses their biological activity and receptor specificity. The ultimate goal is to utilize (64)Cu analogues for positron emission tomography (PET) imaging of breast cancers in humans. Radiochemical purity of each analogue was >92%. The muscle relaxivity assay revealed IC(50) to be 5.3x10(-8) M, 4.4x10(-8) M, 8.1x10(-8) M, 8.1x10(-9) M and Kd values determined by receptor specific cell binding assays were 3.3 nM, 0.33 nM, 0.2 nM and 0.72 nM for TP3805, TP3939, TP3982, and TP4200 respectively. The receptor affinity, using human breast cancer tissues, was 10.93 times greater than normal breast tissues. RT-PCR confirmed increased VPAC1 receptor expression on human breast tumor cells over normal cells and corroborated with autoradiography data. The blood clearance was rapid and in vivo translocation of (64)Cu to plasma protein was <15%. Data demonstrate that these analogues are potent, have uncompromised biological activity and are worthy of further evaluation for accurate PET imaging of human breast cancers and in determining malignant and benign lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.